Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

1995 Vol. 13, No. 2

Cover
Display Method:
Pharmacoeconomics research and drug development
Wei Shui-yi
1995, (2): 67-71.
Abstract:
The pharmacoeconomic studies of a pharmaceutic agent may be planned and conducted early in its development process and continue throughout its use cycle. The driving forces are a rapid increase in population, the lack of health care resources, and cost containment control on the use of medicines. This paper describes pharmacoeconomic researchs at several stages of drug development and the benefit to drug development from pharmacoeconomic studies.
1995, (2): 71-71.
Abstract:
1995, (2): 71-71,111.
Abstract:
Effect of tetrandrine on 45Ca influx in rat aorta in vitro
Tang Zhong-jin, Wang Xiu-ying, Chen Hong, Guan Ying, Zhu Quan-ying, Su Ding-feng
1995, (2): 72-75.
Abstract:
The effects of tetrandrine on calcium influx were studied in rat aorta in vitro.It was found that tetrandrine, similar to verapamil, significantly inhibited high-K+-induced 45Ca influx. But tetrandrine could not inhibit 45Ca influx evoked by phenylephrine, These results suggest that tetrandrine has a specific inhibitary effect on smooth muscle 45Ca influx by inhibiting voltage-operated calcium channel.
1995, (2): 75-75.
Abstract:
Observation on clinical effects of flomoxef in treatment of infections of respiratory tract
Liu You-ning, Yu Bing-xiang, Fang Xiang-qun, Wang Rui
1995, (2): 76-80.
Abstract:
The clinical response and adverse reaction of flomoxef (FMX) in treatment of the patients with respiratory infections were compared with controlled drug-cefmetazone(CMZ) in the study. The results showed that although the age of the patients in group FMZ was older and the serious underground diseases were more than group CMX, but in group FMX, the cured rate was 63.6%, the effective rate was 90.9%, there was no significant difference between the two groups. Especially FMX was the best drug to treat the infections caused by S. aureus(cured rate was 100%). The rate of bacteria clearance of FMX was higher(100%) than CMZ(88.9%), there was no adverse reaction in the group.It is suggested that FMX was a safe and effective antibiotic.
1995, (2): 80-82.
Abstract(2163) PDF (2405KB)(1090)
Abstract:
1995, (2): 82-83.
Abstract:
1995, (2): 83-84.
Abstract:
1995, (2): 85-86.
Abstract:
1995, (2): 86-86.
Abstract(1678) PDF (709KB)(333)
Abstract:
1995, (2): 86-89.
Abstract:
Comparation of dissolution rate of josamycin tablets in different pH medium
Luo Yun, Jie Jin-jie, Li Guo-ying
1995, (2): 90-92.
Abstract:
The article determined dissolution rate of Josamycin tablets in different pH medium. The results showed that T50、Td increased With pH improved.
Chemical compatibility of quinine dihydrochloride injection and co.injection of quinine hydrochloride with gentamycin sulfate injection
Cai Hai-min, Du Shao-rong, Long Bo
1995, (2): 92-93.
Abstract:
Chemical compatibity of quinine dihydrochloride injection and co. injection of quinine hydrochloride with gentamycin sulfate injection in syringe were observed. There were white or light yellow colour precipitation occurrence when the two drugs were mixed directly within 5 minutes. The result showed that they could not be combined for injection.
Effect of azone on the transdermal absorption of puerarin liniment
Wang Jin, Li Ying, Yang Li-bin
1995, (2): 93-95.
Abstract:
The transdermal absorption of puerarin liniment containing 1%,2%,3%of azone,and without azone was studied by isolated pigline skin in vitro. It was demonstrated the liniment containing azone could increase the skin penetration in 12 hours.
Preparation and clinical application of zinc sulfadiazine compound film
Xu Sheng-ji, Zheng Qing-hua, Wang Yi-min
1995, (2): 96-97.
Abstract:
Zinc sulfadiazine compound film(its formula, method of preparation, quality control and clinical application) is introduced. Its formulais composed of zinc sulfadiazine,Dexamethasone and Dyclonine. 45 cases of aphthous ulcers were treated clinically with this film, with the effective rate of 95.56%. It is an agent with quick long effect and convienent for use.
1995, (2): 98-99.
Abstract:
1995, (2): 99-100.
Abstract:
1995, (2): 100-102.
Abstract:
1995, (2): 102-103.
Abstract:
Comparation of methods of quantitative determination for dyclonine hydrochloride solution
Chen Ya, Zhang Zhi-min
1995, (2): 104-105.
Abstract:
We used three methods, argentometric titration, acid-base titration and spectrophotometry,to determine the quantity of dycolonine hydrochloride solution. We compared three methods with analysis of variance. The result showed that they had significantly different from control(p<0.05).
Quantitative determination of tobromycin sulfate injection by optical rotation
Yu Hua-sheng, Xu Jin-xing
1995, (2): 106-108.
Abstract:
A optical rotation method for the quantitative determination of tobromycin sulfate injection was described. The results showed that the method was simpler, rapid, accurate and easier. The average recovery rates was 99.40%, and coefficient of variation was 0.22%, and correlation coefficients of tobromycin sulfate were 0.9999. The product was satisfied of quality control and rapid analysis by the method.
1995, (2): 108-111.
Abstract:
1995, (2): 112-113.
Abstract:
The practice model of hospital pharmacy and pharmaceutical care
Zhang Jun, Wei Shui-yi
1995, (2): 114-118.
Abstract:
The purpose of this article is to provide an overview of the emerging model of hospital pharmacy, pharmaceutical care. The definition, basic elements, core issues and important roles of pharmaceutical care are described.Additionally, we present a brief overview of the differents between pharmaceutical care and clinical pharmacy. Pharmaceutical care will change pharmacy's functions and obligations, which will greatly increase the pharmacists's level of responsibility to patients and ensure the drug therapy for the purpose of achieving definite outcomes that improve the patient's quality of life.
1995, (2): 118-120.
Abstract:
1995, (2): 120-121.
Abstract(1820) PDF (586KB)(316)
Abstract:
1995, (2): 121-123.
Abstract:
1995, (2): 123-124.
Abstract(1682) PDF (784KB)(334)
Abstract:
1995, (2): 124-124.
Abstract(1871) PDF (336KB)(357)
Abstract:
1995, (2): 125-125,89.
Abstract:
1995, (2): 126-128.
Abstract(1888) PDF (992KB)(427)
Abstract:
1995, (2): 128-128.
Abstract(1745) PDF (297KB)(377)
Abstract: